XML 141 R117.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Segment Reporting Information [Line Items]      
Interest income $ 343 $ 385 $ 328
Interest expense (772) (754) (693)
Depreciation and amortization (4,519) (4,676) (5,471)
Research and development (9,752) (10,339) (10,261)
Restructuring costs (632) (776) (651)
Loss on extinguishment of debt   (191)  
Charge related to the settlement of worldwide Keytruda patent litigation 0 0 (625)
Income Before Taxes 8,701 6,521 4,659
Total segment profits      
Segment Reporting Information [Line Items]      
Depreciation and amortization (335) (212) (183)
Income Before Taxes 26,054 24,322 23,644
Total segment profits | Pharmaceutical segment      
Segment Reporting Information [Line Items]      
Depreciation and amortization (243) (125) (160)
Income Before Taxes 24,292 22,495 22,141
Total segment profits | Animal Health      
Segment Reporting Information [Line Items]      
Depreciation and amortization (82) (75) (10)
Income Before Taxes 1,659 1,552 1,357
Total segment profits | Other segments      
Segment Reporting Information [Line Items]      
Depreciation and amortization (10) (12) (13)
Income Before Taxes 103 275 146
Other profits      
Segment Reporting Information [Line Items]      
Income Before Taxes 6 26 481
Unallocated      
Segment Reporting Information [Line Items]      
Interest income 343 385 328
Interest expense (772) (754) (693)
Depreciation and amortization (1,334) (1,378) (1,585)
Research and development (8,853) (9,481) (9,218)
Amortization of purchase accounting adjustments (2,664) (3,056) (3,692)
Restructuring costs (632) (776) (651)
Charge related to termination of collaboration agreement with Samsung (423) 0 0
Loss on extinguishment of debt 0 (191) 0
Gain on sale of certain migraine clinical development programs 0 0 100
Charge related to the settlement of worldwide Keytruda patent litigation 0 0 (625)
Other unallocated, net $ (3,024) $ (2,576) $ (3,430)